Are patient-reported outcomes (PROs) similar in the placebo and the niraparib groups, suggesting that over the course of treatment niraparib does not adversely affect patients’ quality of life? Results of the PRIMA/ENGOT-OV26/GOG-3012 trial begin to elucidate the answer to this question.
The combination of lenvatinib + pembrolizumab exhibited a manageable safety profile and encouraging efficacy in patients with heavily pretreated ovarian cancer, as well as those with a previous history of treatment failure.
In this study, researchers explored whether there is a potential synergistic effect of olaparib when combined with pegylated liposomal doxorubicin, highlighting a potential means to improve tolerability.
When utilized as maintenance therapy after frontline treatment of ovarian cancer in patients with BRCAwt tumors, niraparib improved progression-free survival (PFS), even in the most difficult-to-treat patients.
This real-world study based primarily on community-based practice data showed that a key predictor of time to next treatment and mortality in patients with advanced ovarian cancer was visible residual disease.
Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer.